Menu
No results found.
“Patience reduces risk more reliably than prediction.”
Weekly Share Price & Valuation Overview
ViroGates A/S
ViroGates A/S, an in vitro diagnostics company, develops and sells blood tests for measuring chronic inflammation for the healthcare sector. It offers suPARnostic, a proprietary biomarker used in hospital clinics to guide and inform individuals of their health state, and in hospitals to support clinical decisions and identify high-risk patients, as well as used for a range of acute and chronic health issues, such as cardiovascular disease, type 2 diabetes, and cancer. The company's product includes suPARnostic TurbiLatex, a latex particle-enhanced turbidimetric immunoassay that quantitatively determines the soluble urokinase plasminogen activator receptor (suPAR) level in human K2-EDTA- or lithium heparin plasma samples; suPARnostic ELISA that provides fully quantitative results; and suPARnostic Quick Triage kit for use in the point of care situation for early warning and patient triaging that allows clinicians and nurses to obtain a fast patient prognosis for patient disease severity, progression, and outcome. ViroGates A/S was founded in 2000 and is headquartered in Birkerød, Denmark.
- High gross margin (≥35%) suggests strong pricing power or cost control.
- Quick ratio ≥1.0 indicates obligations can be met without inventory.
- Net cash balance sheet provides flexibility for downturns and investment.
- Negative free cash flow — operations may rely on external financing.
- Market Cap Total equity value of the company (share price × shares outstanding).
- DKK 75.18M
- Enterprise Value Operating value: market cap + total debt − cash.
- DKK 68.35M
- Total Revenue (TTM) Sales over the last twelve months. May be estimated from revenue per share when inconsistent.
- DKK 9.40M
- Gross Profit (TTM) Revenue minus cost of goods sold over the last twelve months. Hidden for financial institutions or if redundant.
- DKK 6.76M
- Revenue per Share (TTM) Total revenue divided by shares outstanding (may be estimated).
- DKK 1.22
- EPS (TTM) Earnings per share over the last twelve months (may be estimated from net income ÷ shares).
- -1.74
- Shares Outstanding
- 7.73M
- Float Shares
- 2.47M
- Implied Shares Outstanding
- 7.73M
- Operating Margin (TTM) Operating income ÷ revenue over the last twelve months (reconciled when possible).
-
-85.08%
- Gross Margin (TTM) Reconciled Strong Gross profit ÷ revenue over the last twelve months (reconciled when possible).
-
71.98%
- Profit Margin (TTM) Net income ÷ revenue over the last twelve months (reconciled when possible).
-
-1.35%
- ROA Return on assets: net income ÷ total assets.
-
-46.04%
- ROE Return on equity: net income ÷ shareholder equity.
-
-1.80%
- Revenue Growth Year-over-year revenue growth.
-
2.40%
- Quick Ratio Adequate Liquid current assets ÷ current liabilities (ex-inventory).
- 1.61
- Debt to Equity Total debt ÷ shareholder equity; leverage.
- 1.06
- Total Cash Cash and equivalents.
- DKK 11.88M
- Total Debt Short + long-term interest-bearing debt.
- DKK 5.04M
- Net Debt Net Cash Total debt − cash (negative = net cash).
- DKK -6.83M
- Operating Cash Flow (TTM) Cash generated by core operations (pre-capex).
- DKK -4.73M
- Free Cash Flow (TTM) Cash after capex; funds buybacks, dividends, and debt paydown.
- DKK -411.00K
- OCF Margin (TTM) Operating cash flow ÷ revenue (TTM).
-
-50.36%
- FCF Margin (TTM) Free cash flow ÷ revenue (TTM).
-
-4.37%
- Margins shown on a TTM basis. “Reconciled” = numerator ÷ TTM revenue for internal consistency.
- Cash Flow section is displayed only when figures are self-consistent (and hidden for financials).
Disclaimer: Information is compiled from publicly available sources and is subject to errors and omissions. It is provided as a guide only and does not constitute investment advice. Please do your own research.